

Corrigendum: Machine Learning Enables Accurate and Rapid Prediction of Active Molecules Against Breast Cancer Cells

Shuyun He^{1,2†}, Duancheng Zhao^{1,2†}, Yanle Ling^{1,2}, Hanxuan Cai^{1,2}, Yike Cai³, Jiquan Zhang⁴* and Ling Wang^{1,2}*

OPEN ACCESS

Edited and reviewed by:

Adriano D. Andricopulo, University of Sao Paulo, Brazil

*Correspondence:

Jiquan Zhang zjqgmc@163.com Ling Wang lingwang@scut.edu.cn [†]These authors have contributed equally to this work

Specialty section:

This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology

> Received: 22 March 2022 Accepted: 12 May 2022 Published: 30 May 2022

Citation:

He S, Zhao D, Ling Y, Cai H, Cai Y, Zhang J and Wang L (2022) Corrigendum: Machine Learning Enables Accurate and Rapid Prediction of Active Molecules Against Breast Cancer Cells. Front. Pharmacol. 13:901513. doi: 10.3389/fphar.2022.901513 ¹Guangdong Provincial Key Laboratory of Fermentation and Enzyme Engineering, Guangdong Provincial Engineering and Technology Research Center of Biopharmaceuticals, School of Biology and Biological Engineering, South China University of Technology, Guangzhou, China, ²Joint International Research Laboratory of Synthetic Biology and Medicine, Guangdong Provincial Engineering and Technology Research Center of Biopharmaceuticals, School of Biology and Biological Engineering, South China University of Technology, Guangzhou, China, ³Center for Certification and Evaluation, Guangdong Drug Administration, Guangzhou, China, ⁴State Key Laboratory of Functions and Applications of Medicinal Plants, College of Pharmacy, Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, China

Keywords: breast cancer, machine learning, graph neural networks, molecular fingerprints, structural fragments

A Corrigendum on

Machine Learning Enables Accurate and Rapid Prediction of Active Molecules Against Breast Cancer Cells

by He, S., Zhao, D., Ling, Y., Cai, H., Cai, Y., Zhang, J., and Wang, L. (2021). Front. Pharmacol. 12: 796534. doi:10.3389/fphar.2021.796534

In the original article, there was a mistake in **Figures 4** and **5** as published. There are some errors in the figure insertion, **Figure 4** is repeated with **Figure 3**, and **Figure 5** is the result of **Figure 4**. The corrected **Figures 4** and **5** appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 He, Zhao, Ling, Cai, Cai, Zhang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.







FIGURE 5 (A) Summary of the optimal models for each fingerprint-based feature. (B) The best models among various fingerprint-based models for different kind of breast cell lines. The optimal models based on (C) AtomPairs, (D) MACCS, (E) Morgan, and (F) PharmacoPFP for different subtypes of breast cell lines.